Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 in BRAF V600-mutant advanced anaplastic thyroid cancer
CTR20212412Phase 2Suspended
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in anaplastic thyroid cancer (ATC), sponsored by Suzhou Runxin Biotechnology. Started Jan 2022; status: suspended.
02
Drugs
HLX208
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on CTR20212412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212412.